OpenEvidence connects clinical questions with cited medical literature

OpenEvidence is a medical search and clinical decision-support service that answers natural-language questions with references to medical literature. Its attraction is the distance it can remove between a clinician’s question and the underlying evidence. The useful evaluation is whether the answer identifies applicable, inspectable evidence and makes uncertainty visible enough for a qualified professional to assess.

01 / ProductCited answers and deeper research address different time horizons

The developer’s current App Store listing describes cited clinical answers, licensed medical content and access for verified U.S. clinicians. It also lists documentation, calling and voice features. Those additions broaden the product, but this blueprint concentrates on the medical search workflow: finding and interpreting information, rather than autonomously diagnosing a patient or selecting treatment.

The company’s DeepConsult announcement distinguishes rapid question answering from a longer research process that searches and synthesizes multiple studies. The practical distinction is useful. A concise reminder between appointments and preparation for a detailed clinical discussion are different reading tasks; they should not be evaluated against the same response-length or speed expectations.

OpenEvidence’s content-partner page identifies licensed material from NEJM, JAMA, Nature and Cochrane, alongside society content. Licensing is a meaningful product input because relevant medical evidence may not be available as unrestricted web text. It establishes access to a body of material, however, rather than a guarantee that each generated sentence correctly represents the cited study.

Primary partners provide useful confirmation. ACEP announced integration of emergency medicine policies and education, while Cochrane confirms a licensing relationship for systematic reviews through Wiley. These relationships make OpenEvidence a relevant AI company to examine without requiring an unsupported claim that it is the best medical assistant.

02 / AudienceClinicians need an evidence assistant they can interrogate

The closest audience is a healthcare professional who already understands the clinical question and needs help locating relevant evidence. A specialist preparing a discussion, an educator explaining competing findings and a clinician checking the scope of a recommendation all have plausible uses. The service can shorten discovery work while the professional remains responsible for relevance and interpretation.

A patient seeking personal medical advice has a different need. The published U.S. clinician access route should not be turned into a promise of unrestricted consumer or worldwide availability. Likewise, finding a medical paper is not the same as establishing that its intervention applies to an individual whose circumstances differ from the study population.

Elicit is useful adjacent coverage for structured literature discovery and research synthesis. Ambience Healthcare addresses documentation and clinical workflow support. OpenEvidence’s search use case sits between medical knowledge access and point-of-care information retrieval; a team should compare the specific task, rather than assuming that every healthcare AI subscription replaces every other one.

03 / WorkflowA proposed evaluation follows the claim back to the study

For an initial evaluation, use a small set of de-identified educational questions that clinicians can review independently. Include one question about a well-established guideline, one involving conflicting evidence and one whose answer depends on a narrow population. Define what a useful answer must contain before seeing the generated response, so fluent writing does not become the evaluation standard.

Ask the question with its relevant population, intervention or exposure, comparison and outcome. These details change which evidence is applicable. A broad question can invite a broad answer; a narrower question makes omissions easier to spot. The aim is to test how reliably the search process preserves those boundaries, rather than to manufacture a difficult prompt that has no realistic clinical use.

Open the references for the consequential claims. Check whether a statement comes from a guideline, a systematic review, an individual trial or a less direct form of evidence. Read the relevant passage and inspect the publication date. A source may exist and still fail to support the strength, population or time frame of the sentence attached to it.

Use a follow-up question to request conflicting findings or limits to generalization. The valuable result is not merely a longer bibliography. It is an explanation of why two studies might disagree, including their populations, methods and outcomes. A reviewer should record whether the assistant identifies the disagreement or smooths it into an unjustifiably confident conclusion.

Then use a longer synthesis task to assess the DeepConsult proposition. Compare the resulting structure with the quick answer: does additional processing surface useful evidence and resolve questions, or mostly repeat the opening summary? This is a proposed evaluation, not a report of testing by Sequenced, and no answer-time or accuracy benchmark is inferred here.

Close the exercise with a short reviewer note separating supported findings, unanswered questions and any statement that required correction. Keep this note with the evidence reviewed. In a real organization, that record can help decide whether the tool is useful for educational discovery, clinical information support or a narrower approved purpose.

04 / PricingFree clinician access still has eligibility and deployment boundaries

The current developer listing states that the product is free for verified U.S. clinicians. The company’s DeepConsult release also described free access for that group. This is the defensible commercial statement from the reviewed evidence; it is not a universal promise about every jurisdiction, account type, institutional integration or future product.

The main website and several policy endpoints returned access errors during this research. The readable developer listing and primary partner announcements support the narrower description above. They do not establish a current enterprise tariff, a worldwide eligibility matrix, query allowances or negotiated service commitments, so those details are not invented here.

For an institutional rollout, the practical cost includes training, evidence-review time and approved information handling. A free individual account does not automatically supply an institution’s integration, contractual and administrative requirements. Compare the effort to retrieve and verify a usable answer with the existing literature-search process, rather than comparing subscription charges alone.

05 / DistinctionsLicensed evidence improves the input, while citations expose the output

Cochrane’s announcement confirms a Wiley licensing partnership covering its systematic reviews. That matters because systematic reviews and single studies answer different questions. A useful assistant should help the reader recognize the type and scope of the evidence, not make all citations appear interchangeable.

The more distinctive product idea is a response that can be checked at the level of an individual assertion. A general search engine leaves much of the synthesis to the reader; an AI answer proposes a synthesis immediately. That can save work, but it also makes checking the relationship between wording and evidence especially important.

Publisher and society partnerships are evidence of content relationships, not independent validation of every model output. Buyers should keep those categories separate. The presence of a respected journal logo does not resolve whether a specific response omitted contrary findings, used an outdated recommendation or confused an association with a causal effect.

06 / QuestionsInstitutional permission and evidence quality remain separate decisions

The MaineHealth notice provides a concrete example of the institutional boundary. It tells its users not to submit protected health information or other sensitive data because MaineHealth does not have an acceptable organizational agreement with OpenEvidence. It also explains that an individually accepted agreement does not authorize sharing MaineHealth information. This is that institution’s policy, not a claim about every customer.

An organization therefore needs to establish its own approved use before clinicians include patient information. The research for this article did not access private contracts or test protected-data handling. Educational questions using appropriately de-identified scenarios allow an initial assessment of retrieval quality without treating an individual registration as institutional authorization.

How current and complete is the answer for the exact question? That remains a response-level question even when the content library grows. Ask reviewers to inspect publication timing, exclusions and the clinical context. A longer list of sources can create false reassurance if none directly addresses the population or decision in front of the user.

07 / DecisionChoose OpenEvidence for a reviewable medical search task

OpenEvidence is a relevant candidate when verified clinicians need faster access to cited medical knowledge and are prepared to inspect consequential claims. Start with a task where a reviewer can judge the sources and the reasoning. A good result is an answer that helps the professional understand the evidence more efficiently while preserving its limits.

Broader adoption should follow demonstrated usefulness and an approved institutional data policy. Keep rapid lookup, extended research and documentation features distinct during evaluation. Their workflows and information requirements differ, and success with one does not automatically validate the others.